Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00723723
First received: July 25, 2008
Last updated: September 12, 2014
Last verified: September 2014

July 25, 2008
September 12, 2014
January 2008
June 2009   (final data collection date for primary outcome measure)
percentage of patients reaching target LDL levels [ Time Frame: 6-8 weeks after first visit and 28-32 weeks after first visit ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00723723 on ClinicalTrials.gov Archive Site
measure patient compliance to treatment as assessed by counting returned tablets [ Time Frame: 6-8 weeks after first visit and 28-32 weeks after first visit ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
Compliance With LDL-Lowering Therapy For Secondary Prevention of Coronary Heart Disease in Real Life Practice

This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients being treated with a statin for secondary prevention of coronary heart disease

  • Coronary Heart Disease
  • Hypercholesterolemia
  • Hyperlipidemia
Drug: Statin
Statin
Other Name: Statin
Patients with coronary heart disease
Patients being treated with a statin for secondary prevention of coronary heart disease
Intervention: Drug: Statin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
555
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • willingness to participate in the study
  • 18 years of age or more
  • clinically established cardiovascular disease to be considered as patients in secondary prevention
  • prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed

Exclusion Criteria:

  • None
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00723723
P05467
No
Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP